[Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome

multicenter randomized double-blind non-inferiority clinical study].

Seong Hee Kang, Yoon Tae Jeen, Ja Seol Koo, Yang Seo Koo, Kyoung Oh Kim, You Sun Kim, Seung Young Kim, Jeong Seop Moon, Jong Jae Park, Il Hyun Baek, Sung Chul Park, Sung Joon Lee, Jong Hun Lee, Rok Seon Choung, Suck Chei Choi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30% reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76%; 90% CI, -10.30-13.82; p=0.81); 69.23% (54 of 78 patients) of patients taking fenoverine and 67.47% (56 of 83 patients) of patients taking trimebutine showed 30% reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability.

Original languageEnglish
Pages (from-to)278-287
Number of pages10
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume62
Issue number5
Publication statusPublished - 2013 Nov 1
Externally publishedYes

Fingerprint

Trimebutine
Irritable Bowel Syndrome
Abdominal Pain
Parasympatholytics
Clinical Studies
fenoverine
Constipation
Smooth Muscle
Diarrhea
Calcium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome : multicenter randomized double-blind non-inferiority clinical study]. / Kang, Seong Hee; Jeen, Yoon Tae; Koo, Ja Seol; Koo, Yang Seo; Kim, Kyoung Oh; Kim, You Sun; Kim, Seung Young; Moon, Jeong Seop; Park, Jong Jae; Baek, Il Hyun; Park, Sung Chul; Lee, Sung Joon; Lee, Jong Hun; Choung, Rok Seon; Choi, Suck Chei.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 62, No. 5, 01.11.2013, p. 278-287.

Research output: Contribution to journalArticle

Kang, Seong Hee ; Jeen, Yoon Tae ; Koo, Ja Seol ; Koo, Yang Seo ; Kim, Kyoung Oh ; Kim, You Sun ; Kim, Seung Young ; Moon, Jeong Seop ; Park, Jong Jae ; Baek, Il Hyun ; Park, Sung Chul ; Lee, Sung Joon ; Lee, Jong Hun ; Choung, Rok Seon ; Choi, Suck Chei. / [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome : multicenter randomized double-blind non-inferiority clinical study]. In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2013 ; Vol. 62, No. 5. pp. 278-287.
@article{ac41868be05c41cba846beecea6b4714,
title = "[Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study].",
abstract = "Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30{\%} reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76{\%}; 90{\%} CI, -10.30-13.82; p=0.81); 69.23{\%} (54 of 78 patients) of patients taking fenoverine and 67.47{\%} (56 of 83 patients) of patients taking trimebutine showed 30{\%} reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability.",
author = "Kang, {Seong Hee} and Jeen, {Yoon Tae} and Koo, {Ja Seol} and Koo, {Yang Seo} and Kim, {Kyoung Oh} and Kim, {You Sun} and Kim, {Seung Young} and Moon, {Jeong Seop} and Park, {Jong Jae} and Baek, {Il Hyun} and Park, {Sung Chul} and Lee, {Sung Joon} and Lee, {Jong Hun} and Choung, {Rok Seon} and Choi, {Suck Chei}",
year = "2013",
month = "11",
day = "1",
language = "English",
volume = "62",
pages = "278--287",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "5",

}

TY - JOUR

T1 - [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome

T2 - multicenter randomized double-blind non-inferiority clinical study].

AU - Kang, Seong Hee

AU - Jeen, Yoon Tae

AU - Koo, Ja Seol

AU - Koo, Yang Seo

AU - Kim, Kyoung Oh

AU - Kim, You Sun

AU - Kim, Seung Young

AU - Moon, Jeong Seop

AU - Park, Jong Jae

AU - Baek, Il Hyun

AU - Park, Sung Chul

AU - Lee, Sung Joon

AU - Lee, Jong Hun

AU - Choung, Rok Seon

AU - Choi, Suck Chei

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30% reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76%; 90% CI, -10.30-13.82; p=0.81); 69.23% (54 of 78 patients) of patients taking fenoverine and 67.47% (56 of 83 patients) of patients taking trimebutine showed 30% reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability.

AB - Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30% reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76%; 90% CI, -10.30-13.82; p=0.81); 69.23% (54 of 78 patients) of patients taking fenoverine and 67.47% (56 of 83 patients) of patients taking trimebutine showed 30% reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability.

UR - http://www.scopus.com/inward/record.url?scp=84903000431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903000431&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 278

EP - 287

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 5

ER -